---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-25-000013"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:30:58.295017+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q4 software revenue $79.7M (+16% YoY); 2025 outlook: rev growth 10-15%, drug disc rev $45-50M

## Summary
- Q4 2024 total revenue $88.3M (+19% YoY); software revenue $79.7M (+16% YoY).
- Full-year 2024 net loss $187.1M vs net income $40.7M in 2023; non-GAAP net loss $191.4M.
- Cash, equivalents, and marketable securities $367.5M at Dec 31, 2024; received $150M upfront from Novartis in Jan 2025.
- 2025 guidance: software revenue growth 10-15%; drug discovery revenue $45-50M; software gross margin 74-75%; OpEx growth <5%.
- Expanded collaboration with Lilly (undisclosed target); Novartis collaboration cleared with $150M payment received.

## SEC filing metadata
- accession: 0001490978-25-000013
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097825000013/0001490978-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097825000013/sdgr-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-25-000013
- JSON: https://secwatch.observer/filing/0001490978-25-000013.json
- Plain text: https://secwatch.observer/filing/0001490978-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.